+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Proton Therapy for Pediatric Hodgkin Lymphoma



Proton Therapy for Pediatric Hodgkin Lymphoma



Pediatric Blood and Cancer 63(9): 1522-1526



Compared to X-ray radiation therapy, proton therapy (PT) reduces the radiation dose to organs at risk, which is expected to translate into fewer second cancers and less cardiac morbidity decades after treatment. The Children's Oncology Group high-risk pediatric Hodgkin lymphoma (PHL) protocol, AHOD1331, allows the use of PT, yet limited data exist on the use of PT in PHL. Between 2010 and 2014, 22 pediatric patients were treated with PT for PHL at our institution: 7 intermediate-risk patients, 11 high-risk patients, and 4 relapsed patients. The patients' age ranged from 6 to 18 years old. Median follow-up was 36 months. All patients received chemotherapy before PT. The 2-year and 3-year overall survival rates were both 94%, and the progression-free survival rate was 86%. Recurrences occurred in three high-risk patients: one isolated in-field cervical lymph node and two in-field and out-of-field. All recurrences occurred within 5 months of completing PT. No PT-related grade 3 or higher acute or late complications were observed. PT for PHL showed no short-term severe toxicity and yields similar short-term control to recently published large multi-institutional clinical trials.

(PDF emailed within 0-6 h: $19.90)

Accession: 058654483

Download citation: RISBibTeXText

PMID: 27149120

DOI: 10.1002/pbc.26044


Related references

(P124) dosimetric comparison of three-dimensional conformal proton radiotherapy and intensity-modulated proton therapy for treatment of pediatric hodgkin lymphoma. Oncology 29(4 Suppl 1): -, 2015

Proton therapy in a pediatric patient with stage III Hodgkin lymphoma. Acta Oncologica 52(3): 592-594, 2013

Can treatment of pediatric Hodgkin's lymphoma be improved by PET imaging and proton therapy?. Strahlentherapie und Onkologie 189(1): 54-61, 2013

Dosimetric comparison of involved-field three-dimensional conformal photon radiotherapy and breast-sparing proton therapy for the treatment of Hodgkin's lymphoma in female pediatric patients. International Journal of Radiation Oncology, Biology, Physics 81(4): E667-E671, 2012

Relapsed/refractory pediatric B-cell non-Hodgkin lymphoma treated with rituximab combination therapy: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group. Pediatric Blood & Cancer 63(10): 1794-1799, 2016

Proton therapy patterns-of-care and early outcomes for Hodgkin lymphoma: results from the Proton Collaborative Group Registry. Acta Oncologica 55(11): 1378-1380, 2016

Proton therapy for Hodgkin lymphoma. Current Hematologic Malignancy Reports 9(3): 203-211, 2015

Proton therapy in the management of non-Hodgkin lymphoma. Leukemia and Lymphoma 56(9): 2608-2612, 2016

Cardiac sparing with proton therapy in consolidative radiation therapy for Hodgkin lymphoma. Leukemia and Lymphoma 51(8): 1559-1562, 2010

Pediatric Oncology Group experience with modified LSA2-L2 therapy in 107 children with non-Hodgkin's lymphoma (Burkitt's lymphoma excluded). Cancer 55(2): 323-336, 1985

Involved-node proton therapy in combined modality therapy for Hodgkin lymphoma: results of a phase 2 study. International Journal of Radiation Oncology, Biology, Physics 89(5): 1053-1059, 2014

Improving the therapeutic ratio in Hodgkin lymphoma through the use of proton therapy. Oncology 26(5): 456-9, 462-5, 2012

Proton therapy to the subdiaphragmatic region in the management of patients with Hodgkin lymphoma. Leukemia and Lymphoma 56(7): 2019-2024, 2016

Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. Cancer 110(1): 179-185, 2007

Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential. Journal of Applied Clinical Medical Physics 16(5): 167–178, 2016